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Acceleration of the PanIN Development in Mice Expressing Oncogenic K-Ras Due
to a High Fat Diet
Bincy Philip
Supervisory Professor: Craig D. Logsdon, Ph.D.
Obesity is postulated to be one of the major risk factors for pancreatic
cancer, and recently it was indicated that an elevated body mass index (BMI
correlates strongly with a decrease in patient survival. Despite the evident
relationship, the molecular mechanisms involved are unclear. Oncogenic mutation
of K-Ras is found early and is universal in pancreatic cancer. Extensive evidence
indicates oncogenic K-Ras is not entirely active and it requires a triggering event to
surpass the activity of Ras beyond the threshold necessary for a Ras-inflammation
feed-forward loop. We hypothesize that high fat intake induces a persistent low level
inflammatory response triggering increased K-Ras activity and that Cox-2 is
essential for this inflammatory reaction. To determine this, LSL-K-Ras mice were
crossed with Ela-CreER (Acinar-specific) or Pdx-1-Cre (Pancreas-specific) to
“knock-in” oncogenic K-Ras. Additionally, these animals were crossed with Cox-2
conditional knockout mice to access the importance of Cox-2 in the inflammatory
loop present. The mice were fed isocaloric diets containing 60% energy or 10%
energy from fat. We found that a high fat diet increased K-Ras activity, PanIN
formation, and fibrotic stroma significantly compared to a control diet. Genetic
deletion of Cox-2 prevented high fat diet induced fibrosis and PanIN formation in
oncogenic K-Ras expressing mice. Additionally, long term consumption of high fat
diet, increased the progression of PanIN lesions leading to invasive cancer and
decreased overall survival rate. These findings indicate that a high fat diet can
v

stimulate the activation of oncogenic K-Ras and initiate an inflammatory feed
forward loop requiring Cox-2 leading to inflammation, fibrosis, and PanINs. This
mechanism could explain the relationship between a high fat diet and elevated risk
for pancreatic cancer.
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CHAPTER 1: LITERATURE REVIEW
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1.1 Introduction
Currently, pancreatic ductal adenocarcinoma (PDAC) is the fourth deadliest
malignancy in the United States and every year over 43,000 Americans are
diagnosed with this disease (77). Majority of these patients will die within a year of
diagnosis and mortality rates have increased in the last decade (79). Only 5% of
patients will survive up to five years after diagnosis (77). It is estimated that 19,480
men and 18,980 women will die from pancreatic cancer in 2013 alone (78). The
severity of this disease stems from the lack of early detection and effective
treatments with surgical resection as the only treatment presently. However, for
most patients, by the time of diagnosis, the cancer has already metastasized and it
is too late for surgical resection to be effectual.
1.2 Early Stages of Pancreatic Cancer
1.2.1 Bi-functional Roles of the Pancreas
The pancreas is an irregularly shaped, flat digestive gland that is located
behind the stomach and runs along the duodenum and spleen (Figure 1.1). The
location of the organ makes it a difficult for visualization using current methods of
detection and increases the risk of cancer to go undetected. The pancreas consists
of three types of cells with diverse functions that are either part of the exocrine or
endocrine gland (40). The exocrine gland of the pancreas is comprised of acini that
secrete digestive enzymes such as zymogens and ductal cells that allow for
transport of fluid drainage from the acinar cell to the stomach as well as secretion of
biocarbonate for neutralization of stomach acid (40). The pancreatic duct, running
through the entire pancreas, is the main duct for the secretion of pancreatic fluid
2

from the exocrine gland into the duodenum and merges with the bile duct (Figure
1.1). Islets of Langerhans make up the endocrine gland and are responsible for the
body’s insulin production (40). Together these compartments are necessary for the
normal function of the gastrointestinal tract. Cancer in the pancreas can interfere
with proper digestion due to the destruction of bile ducts and reduction of pancreatic
enzymes produced.

Figure 1.1: Diagram of the major properties of the pancreas. Animated representation
of the major ducts and cells comprising the pancreas.

3

1.2.2 Pancreatic Intraepithelial Neoplasia
Currently, there is major controversy present between the origin of pancreatic
ductal adenocarcinoma, whether it derives from duct cells or acinar cells
transforming into pancreatic intraepithelial neoplasias (PanINs), noninvasive ductal
lesions classified as precursors to pancreatic cancer (51). Recent evidence
supports the initiation of PanIN formation to be of acinar cell origin in which acinar
cells differentiate into ductal precursor lesions in a process called acinoductal
metaplasia (29). Specifically in mice it has been recorded that mouse acinar cells
can transdifferentiate into preneoplastic ductal lesions in the presence of oncogenic
K-Ras (29).
Despite the controversy, the transformation from normal epithelial cells to
PanINs requires morphological changes to the cell and nuclei (Figure 1.2). PanIN1a lesions are classified as the first stage of transformation of the normal flat
epithelial cells, acinar or ductal, into columnar cells with the visible presence of
mucin production (30, 47, 50, 70). The cells are usually uniform, basally oriented,
and the nucleus remains round. However, these cells can transform further and
form papillary protrusions in which acinar atrophy becomes highly prevalent,
becoming PanIN-1b lesions. PanIN-2 lesions are distinguishable from PanIN-1 in
the development of cytologic atypia accompanied by loss of cellular polarity causing
overcrowding (32). The nuclei become elongated and the cells appear to be pseudo
-stratified. The progression to PanIN-3 lesions are characterized by extensive
nuclear atypia, cellular crowding, and cells form papillai budding off into the ductal
lumen (30, 32, 47, 50, 70). The presence of PanIN lesions is common in healthy
individuals with the risk increasing with age, and they do not always lead to
4

pancreatic cancer. Progression to PDAC requires the further activation of oncogenic
mutations such as K-Ras and tumor suppressors’ p16 and p53 to drive this reaction.

Figure 1.2: Progression of PanIN formation leading to invasive PDAC. Schematic
of the different stages of PanIN development starting from transformation of normal
epithelial cells to columnar cells leading to PanIN-1a lesions. This is followed by PanIN1b lesions characterized by papillary protrusions of cells with changes in nuclear
morphology. PanIN-2 lesions consist of nuclear atypia accompanied by
psuedostratification and overcrowding of cells. These lesions develop into PanIN-3
lesions in which the nuclei are elongated and overcrowded with clusters of cells
budding off into the lumen. This progression of PanIN lesions can eventually lead to
invasive carcinoma. The initiation of PanIN formation is due to genetic alterations such
as mutation in K-Ras leading to accumulation of other oncogenic mutations in p16 and
p53. PanIN pictures were reprinted with permission from The American Journal of
Surgical Pathology, Pancreatic intraepithelial neoplasia: a new nomenclature and
classification system for pancreatic duct lesions, Hruban, R.H., et al., 2001. 25(5):
p.579-86, Copyright 2001.
1.2.3 Inflammation and Fibrosis
In the initiation of the metaplastic transformation of normal pancreas cells to
ductal precursors, inflammation is highly required. Recent evidence from our lab
has shown the importance of an inflammatory mediator to drive PanIN formation
(14). The link between inflammation and cancer was noted back in 1863 by Rudolf
Virchow who observed the presence of leukocytes in neoplastic tissues throughout
5

tumor areas and stroma (4). This area of neoplastic growth consists of immune
cells, such as macrophages, dendritic cells, and lymphocytes, which are designed
to migrate to sites of infection and activate unique mechanisms through release of
pro-inflammatory cytokines to eliminate the pathogens and allow for tissue
reformation (4).

However, this network of inflammatory mediators, although

necessary to eliminate infection, enhances survival, proliferation, and growth of
these tumor cells through DNA damage, angiogenesis, invasion, metastasis, and
evading immunity (4, 55). Therefore, chronic inflammation resulting in a
“overhealing” as suggested by Sir Alexander Haddow, drives pathogenesis (24, 25).
The activation of inflammation in the pancreas leading to the recruitment of
the immune system is initiated by damaged acinar cells (55, 66, 67). Environmental
factors such as obesity and genetic mutations are major contributors to
inflammation in the pancreas. Once inflammation is initiated by acinar cells and
stromal elements undergoing cellular mutations, quiescent pancreatic stellate cells
(PSCs), myofibroblast cells, are activated. Activated PSCs travel to sites of injury
and develop extracellular matrix (ECM) proteins, predominately alpha smooth
muscle actin, collagen I and III, fibronectin, and proteoglycans, leading to fibrosis in
the pancreas to help repair the damage (18, 19, 55, 65). Pancreatic cancer is
known as a fibrotic tumor with 90% of the tumor volume

with pronounced

desmoplastic reaction in the stroma lead by PSCs releasing increased levels of
ECM deposition exceeding the rate of ECM degradation (46, 58, 65).
Overproduction of ECM proteins by stellate cells correlates with poor prognosis of
pancreatic cancer. Additionally, stromal cells are manipulated by inflammatory cells
and tumor cells to promote tumor cell growth, invasion and migration, indicating the
6

importance of inflammation and fibrosis in the initiation of PanIN formation (2, 57,
65).
1.2.4 Oncogenic K-Ras mutation
Oncogenic mutation in K-Ras is common in 15% of all cancers with the
highest prevalence seen in pancreatic cancer with mutant K-Ras activated in more
than 90% of cases (1, 17, 35, 52). The most common oncogenic mutation in K-Ras
reported in PDAC is most predominately due to a point mutation in codon 12 (16).
The earliest appearance of mutant K-Ras is at PanIN-1 development, the first stage
of precursor lesions (31, 51). A meta-analysis of studies on K-Ras mutations
showed an increase in K-Ras mutations starting with 36%, 46%, and 87% of lesions
containing mutant K-Ras as PanIN lesions progressed from PanIN-1 to PanIN-3
(47). This increase of mutant K-Ras in the presence of PanIN lesions is not seen in
PanINs that are present in chronic pancreatitis or normal pancreas tissue (47).
Since mutations in K-Ras are seen in the earliest genetic event occurring
during transformation of normal epithelial cells to PanIN-1 lesions, it suggests that
this mutation acts as a gatekeeper for this phenomenon. The activation of
oncogenic mutation in K-Ras results in the accumulation of mutations in p53 and
p16 which is required for the progression into higher grade PanIN lesions (56, 70)
(Figure 1.2). A genetic loss of function mutation in the tumor suppressor, p16, is
predominately present in PanIN-2 development and is due either by a homozygous
deletion,

intragenic

mutation

with

loss

of

second

allele,

or

promoter

hypermethylation (39, 43, 70). Loss of p16 can eventually lead to oncogenic
inactivation of p53 by the loss of one allele and mutation in the second allele
7

allowing for uncontrolled cell growth and genetic instability (70). Activation of
oncogenic K-Ras is the first of these genetic mutations and is essential for the
further activation of mutations to drive carcinogenesis.
1.3 Endogenous K-Ras Activity and Signaling
Ras is a 21 kilo Dalton guanine nucleotide binding protein (G-protein) that
regulates cellular functions involved in cell proliferation, survival, and differentiation.
Ras genes were first identified as the Harvey and Kirsten sarcoma retroviruses and
named Ras for rat sarcoma. There are three isoforms of Ras that are considered
proto-oncogenes: H-Ras, N-Ras, and K-Ras (15). In a normal cell, Ras is bound to
guanosine diphosphate (GDP) and remains in an inactive state (Figure 1.3). In
response to growth factors, cytokines, and other exogenous signals, guanine
nucleotide exchange factors (GEFs) will remove the GDP and bind guanosine
triphosphate (GTP) switching the Ras protein to an active state by triggering a
conformational change in the G domain allowing for high affinity for downstream
targets (8, 15, 74, 86). Once Ras is bound to GTP and active, it can activate the
downstream effector molecules, such as phosphoinositide 3-kinase (PI3-K),
mitogen-activated protein kinase (MAPK), and Ral that are responsible for normal
cellular function (39, 43, 70) (Figure 1.3). The molecular switch of Ras oscillates
back to inactive, making the activity transient due to intrinsic GTP hydrolysis and is
further enhanced by GTPase activating proteins (GAPs). GAPs are recognized as
negative regulators of active Ras and aids in the hydrolysis of GTP to GDP
conforming Ras back to an inactive state (8, 15).

8

Figure 1.3: Endogenous Ras vs. oncogenic K-Ras signaling. Diagram of
signaling pathways of endogenous and oncogenic K-Ras and the difference in Ras
activity. Endogenous K-Ras is bound to GDP in an inactive state and is activated by
GEFs which remove GDP and bind GTP. GTP bound Ras can now activate its
downstream effector molecules Raf, PI3K, and NF-κB leading to formation of
phospho-ERK, phospho-AKT, and activation of Cox-2 leading to PGE2 which are
necessary for cell growth, survival, and differentiation. Endogenous K-Ras due to
intrinsic GTPase activity and interaction with GAPs return back to its inactive state
through hydrolysis of GTP to GDP. In contrast, oncogenic K-Ras mutation blocks
GAP interaction with Ras-GTP prolonging Ras activity. However, oncogenic K-Ras
is still bound to GDP and must be stimulated by an inflammatory mediator for GEFs
to move it to an active state. Once oncogenic K-Ras is active, it can activate
downstream targets. Activation of Cox-2 leads to a positive feed forward loop
enhancing K-Ras activity resulting in in prolonged K-Ras downstream signaling.
9

Ras binds and activates several different effector molecules and of those the
most studied is the kinase Raf (15, 54, 69) (Figure 1.3). Ras-GTP binds to the Nterminal Ras binding domain (RBD) and the cysteine rich domain (CRD) of the Raf
effector molecule. Normally Raf is in the cytoplasm but on activation by Ras-GTP,
Raf is recruited to the plasma membrane (7, 15, 80, 82). Active Raf can now
phosphorylate downstream effectors MEK1 and MEK2 which can go on to activate
ERK1 and ERK2 through phosphorylation of threonine and tyrosine residues on
their activation regions. ERK is involved in phosphorylation of transcription factors,
kinases, and phosphatases (15). The Ras/Raf/MEK/ERK pathway was the first Ras
effector signaling pathway determined.
Additionally, PI3-K is another effector molecule of Ras that is necessary for
cellular function (Figure 1.3). PI3-K consists of heterodimers with a p85 regulatory
subunit and a p110 catalytic subunit (15). Once PI3-K is activated, it recruits the
complex to plasma membrane and phosphorylates phosphatidylinositol-(4, 5)biphosphate (PIP2) to make phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3). PIP3
is then involved in activating AKT resulting in the downstream signaling pathways.
1.4 Oncogenic Activity of Ras
Ras mutations are common in many cancers with varying mutation rates
depending on the isoform of Ras. The most common mutation of Ras is seen in the
K-Ras gene and accounts for more than 85% of cancer cases (15). In pancreatic
cancer, an oncogenic mutation in K-Ras is due to a point mutation in codon 12
which limits the ability of GAPs to perform GTP hydrolysis (39, 43, 70). Point
mutation in codon 12 blocks GAP interaction with Ras preventing it from removing
10

GTP and binding GDP so Ras remains active. Therefore, once oncogenic K-Ras is
bound to GTP, it displays prolonged signal and is often said to be constitutively
active (52). Recently, this idea has been questioned and shown to not be the case.
Contrary to common belief, oncogenic K-Ras is inactive until stimulated by an
exogenous signal (14) (Figure 1.3). Once it is activated, it is slow to return to basal
levels. Activated oncogenic K-Ras can stimulate downstream targets and can
generate inflammatory mediators through activation of NF-κB, Stat3, and others (14,
20, 33). Activation of oncogenic K-Ras beyond a threshold initiates a Rasinflammation feed-forward loop involving Cox-2 where K-Ras activity is further
increased and sustained (14, 33). Cox-2 activates prostaglandin E2 which can
stimulate the activation of oncogenic K-Ras (Figure 1.3). Therefore, while the
normal activity of Ras is short-lived, the activity of oncogenic K-Ras is constitutive
and sustained after activation.
1.5 Risk Factors of Pancreatic Cancer
Genetic and environmental factors can lead to an elevated risk of developing
pancreatic cancer in an individual’s lifetime (Table 1.1). Genetic factors or the nonmodifiable risk factors consist of aspects that the individual has no control over.
These non-modifiable risk factors include age, gender, race, and heredity. (Table
1.1). The risk for developing pancreatic cancer increases as an individual gets
older, with a significant increase in cancer incidence after age 50 (59, 79).
Specifically, the incidence rate in men jumped from 1.2 for men 35-39 years of age
to 100.5 in men that are 85 years of age and a similar trend was seen in women
(79). Men are more susceptible to developing pancreatic cancer than women and
the risk increases after 35 years of age (79).
11

Non-modifiable Risks

Modifiable Risks

Age

Cigarette Smoking

Race

Alcohol

Gender

Poor Diet

Hereditary

Obesity
Chronic Pancreatitis
Diabetes

Table 1.1 Table of potential risk factors of PDAC. Compilation of non-modifiable
and modifiable risk factors of PDAC.

Another major non-modifiable risk factor is race, with the highest pancreatic
cancer

incidence

rates

found

in

African

Americans

(59,

79).

Asian

Americans/Pacific Islanders appear to have the lowest mortality rates compared to
all races (59, 79). Hereditary factors can also put individuals at risk for PDAC due to
the high prevalence of the cancer in one’s family. About 5-10% of PDAC patients
have a family history of pancreatic cancer (59, 79).
Although many risk factors are uncontrollable, there are several modifiable
risk factors that can are preventable. These factors include smoking, alcohol,
dietary factors, obesity, chronic pancreatitis, and diabetes (Table 1.1). Smokers
have twice the risk of developing pancreatic cancer than non-smokers and 20% of
PDAC cases are due to this habit. The risk of developing PDAC increases with
prolonged use of cigarettes (9, 34, 49, 79). Risk due to alcohol use, on the other
12

hand, is not well determined but several studies show a positive association (21,
79). Of these modifiable risk factors, obesity has taken the spotlight recently and
has become recognized as a major risk factor for pancreatic cancer. Several studies
support a strong correlation between obesity and a 20% higher risk for PDAC
development (3, 6, 79).
1.6 Obesity as a Risk Factor
1.6.1 Obesity and Inflammation
The growing trend of obesity has been increasingly prevalent in the United
States and nearly two thirds of adults are obese or markedly overweight (12). This
epidemic of obesity is prevalent in developing Westernized societies and could be
especially related to consumption of diets rich in high levels of fat (76). In 2000,
there were nearly 300 million obese adults worldwide and that number almost
doubled in eight years (72). Along with adult obesity, childhood obesity is strikingly
increasing with 40 million children under 5 years of age considered overweight in
2011 (61).
Obesity is a disorder where there is an imbalance between energy intake and
energy expenditure resulting in an accumulation of excess adipose tissue, and
energy storing organ. Adipocytes increase in size to store fatty acids but these cells
have limited storing capacity. For this reason, obesity is associated strongly with a
chronic low grade inflammatory condition leading to metabolic dysfunction due to
fatty acid deposition in other organs such as the liver (28, 63, 75). Systemic
inflammation caused by obesity is primarily thought to derive from excess adipose
tissue releasing high levels of pro-inflammatory molecules called adipokines and
13

cytokines such as TNF-α (28, 63). Most adipokines such as leptin, an adipose
tissue specific protein regulating food intake, are seen to be elevated in obesity
(63). In contrast, adiponectin, a protein which regulates fatty acid breakdown and
glucose levels, is decreased. Leptin mainly binds to transmembrane receptor (OBR)
or interleukin-6 (IL-6) allowing for downstream signaling through ERK and JAKSTAT3 (41). In cancer, leptin stimulates cell proliferation through activation of the
MAPK pathway (41). TNF-α and IL-6 is produced by inflammatory cells in adipose
tissue.

Production of IL-6 promotes cell proliferation and metastasis through

activation of JAK-STAT (41). Further, TNF-α is upregulated in a state of obesity
and is known to bind to TNF receptors that lead to activation of NF-κB (41).
Activation of NF-κB can lead to activation of Cox-2 promoting an inflammatory state.
Increased systemic inflammation in obese individuals is linked with the infiltration of
macrophages in adipose tissue (48, 63, 85). Additionally, excess adipose tissue is
comprised of fibroblasts which release extracellular matrix proteins aiding in the
development of fibrosis and contributes to metabolic dysfunction (63). Obesity
induced systemic inflammation and fibrosis can lead to cardiovascular disease as
well as an elevated risk for cancer (5).
1.6.2 Obesity and Cancer Risk
Obese and overweight individuals are classified based on one’s body mass
index (BMI), a simple index measuring adiposity based on a person’s height and
weight in which an elevated BMI greater than 25 kg/m2 indicates the individual is
overweight or obese if BMI is above 30 kg/m2 (61, 83). Increased BMI is
predominately correlated to morbidity and mortality due to cardiovascular diseases
and the incidence of type 2 diabetes (62, 63, 72). However, several studies have
14

also linked elevated BMI to a greater risk of developing certain types of cancer (11,
12, 62, 68, 72, 76, 83) (Figure 1.4). It is estimated that in 2013, 580,350 Americans
will die of some type of cancer (78, 79). Currently, between 7-41% of cancer deaths
are attributable to excess body weight and that risk increases with obesity at a
young age (61). Interestingly, the reduction of body weight, as seen in patients
undergoing bariatric surgery can reduce cancer incidence, indicating that weight
loss can prevent cancer risk and could potentially decrease the 1,600 deaths due to
cancer each day (71, 79). Most consistently significant positive linear trends in
death rates were seen in colorectal, endometrial, breast, uterine and kidney cancers
with the highest observed relative risk seen in uterine cancer (11, 12).
1.6.3 Obesity and Pancreatic Cancer
Although these are the most common types of cancers affected by excess
body weight, epidemiological studies also indicate there is a relationship between
adiposity and cancers of esophagus, gastric cardia, pancreas, gallbladder, and liver
(11, 12). Specifically, recent studies have shown a two-fold increased risk for
pancreatic cancer in obese individuals (12). There has been conflicting results
regarding the association between high BMI and pancreatic cancer. However,
majority of epidemiology and cohort studies have found a strong linear relationship
between excess body weight and increased risk for pancreatic cancer (3, 44, 45)
(Figure 1.4).
Excess body weight has been recognized as a major contributor to promoting
pancreatic cancer and increases the risk by 20% (3, 6, 10, 12, 44, 45, 53, 55, 68,
79) . Individuals who are obese at a young age, ages 20-49 has an increased risk
15

for developing pancreatic cancer and an earlier age of disease onset (45, 79).
Further, there was also a strong correlation between obesity at an older age and
decreased survival in PDAC patients (45). Since accumulating evidence shows a
direct linear relationship between excess body weight and pancreatic cancer risk, it
is even more important to determine the molecular mechanisms involved.

Figure 1.4: Relative cancer risk assessment through BMI. Relative risk
assessment of overweight and obese individuals according to body mass index.
This data was taken from Calle, E. E., and R. Kaaks. 2004. Overweight, obesity
and cancer: epidemiological evidence and proposed mechanisms. Nature Reviews
Cancer 4:579-591. BMI, body mass index, ND, not determined.
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1.7 High Dietary Fat Increases Cancer Risk
With the growing epidemic of obesity, it is important to determine the dietary
factors that could put individuals at risk for developing obesity mediated disorders
such as cancer. A recommended healthy balanced diet should consist of 65% of
one’s caloric intake made up of carbohydrates, 20-35% fat, and 10-35% protein
(36). Since obesity is an imbalance between energy intake (amount of calories
consumed) and energy expenditure (amount of calories lost), it is important to
consider the quality and quantity of food consumption. It is evidenced that dietary fat
should be consumed sparingly and that fat metabolism is complex compared to the
breakdown of protein or carbohydrates. Several studies have shown that high fat
consumption can enhance the growth of certain types of cancer, specifically
pancreatic cancer (42, 73).

Specifically, it was demonstrated that high fat diet

induced obesity leading to low grade inflammation and accelerated PanIN
development in a less specific K-Ras mouse model (42). Orthotopic implantation of
Mia PaCa2 tumor cells into mice fed high fat diet showed dramatic increase in
pancreatic tumor burden (84). Although the association of high fat and cancer
development is known, the mechanisms of how high fat diet induces obesity and
how obesity induces cancer initiation is not well understood.
1.8 Mouse Models of Pancreatic Cancer
To prove further that high fat diet induced obesity is a potential major
contributor to the development of pancreatic cancer; different mouse models can be
used. The most commonly used K-Ras mouse model is known as Pdx-Cre-1-KRasG12D and it is unique in that it utilizes a developmental promoter, Pdx-1, also
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known as insulin promoting factor (IPF), to drive expression of Cre recombinase, a
tyrosine recombinase enzyme made from P1 bacteriophage that is used to drive
site specific recombination events (23, 27, 64). Since Pdx-1 is a transcription factor
that is present early in the development of the pancreas and is known to lead to the
differentiation of progenitor cells that give rise to acinar, ductal, and islet cells, using
this promoter to drive Cre expression results in Cre expression in every cell of the
pancreas. Pdx-1-Cre-K-RasG12D is a mouse made from a recombination of Pdx-1Cre with a mouse using an endogenous promoter to knock-in mutant K-Ras
expression. Mutation in K-Ras in this model is due to a point mutation that changes
the glycine to aspartic acid at the 12th residue, as is commonly seen in pancreatic
cancer. The expression of mutant K-Ras is blocked by loxP-stop-loxP cassette
which requires Cre activation for cleavage of this site and to drive oncogenic K-Ras
expression in the entire pancreas at conception. Additionally, another widely used
pancreatic cancer mouse model is known as p48 Cre -K-RasLSL-G12D/+, which similar
to the Pdx-1-Cre-K-RasG12D, employs a developmental promoter p48 that is
expressed later in development than Pdx-1 (26). This promoter is used to drive Cre
expression and recombination leading to mutant K-Ras in all adult pancreatic cells
(23).
Since Pdx-1-Cre-K-RasG12D and p48Cre -K-RasLSL-G12D/+ results in nonspecific
expression of K-Ras during early embryonic development of the pancreas, cell type
specific promoters were also used to drive Cre expression. As mentioned
previously, the origin of pancreatic cancer is known to be ductal cells. However, due
to the growing evidence that acinar cells can transform into ductal precursor lesions,
an acinar specific promoter, elastase, is currently used. Short elastase promoters
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have been used but these results in low efficiency of expression (37). Recently, full
length elastase promoter was used to drive Cre expression that was tamoxifen
regulated with 100% efficiency for acinar cells (37). Although there are various
models using the elastase promoter, our lab specifically used a full length elastase
promoter to drive Cre that is bound to an estrogen receptor (ER) and crossed with
Tuveson K-Ras model to result in mouse model called LSL/BAC (37). When Cre is
activated by tamoxifen binding to its estrogen receptor, Cre recombinase removes
loxP sites and knock-ins expression of endogenous levels of mutant K-Ras.
Recombination results in mutant K-Ras expression specifically to the acinar cells of
the pancreas (37, 38). This model gives greater control of the expression of K-Ras
and presents a more accurate representation of what could occur in the human
condition.
All these mouse models develop PanINs that are histologically similar to
human pathology. Furthermore, they are also known to express mucins,
cytokeratin-19, Cox-2, and other factors that are seen to be highly present in human
PanINs (23, 27).

1.9 Study Perspective
In the current study, we investigated the role of obesity in animals with an
oncogenic mutation in K-Ras in the pancreas by treating animals with a high fat diet
to induce obesity. Previously, a high fat diet was shown to prompt inflammation and
accelerate development of PanIN lesions in mice harboring a developmental
expression of oncogenic K-Ras (42).

This model, however, had spontaneous

formation of PanINs. We hypothesized that a consumption of high fat diet has the
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potential to act as an inflammatory stimulus to activate oncogenic K-Ras signaling
and initiate the development of PanIN lesions. To test this hypothesis, we used an
elastase-BAC mouse model that expresses oncogenic K-Ras specifically in the
adult acinar cells (LSL/BAC) and has low levels of spontaneous PanIN development
(37). Since Cox-2 is known to be critical in inflammatory mechanisms, we tested
whether the expression of Cox-2 in acinar cells would be critical for high fat diet
induced pathogenesis in animals with oncogenic K-Ras mutation. Determining the
risk of a high fat diet in the presence of mutant K-Ras is essential because of the
increasing numbers of obese Americans every year. The number of pancreatic
cancer cases could be decreased by simple prevention tactics.
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CHAPTER 2. MATERIALS AND METHODS
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2.1 Genetically constructed transgenic animals.
All genetically engineered transgenic animals were acquired from the Mouse
Models of Human Cancer Consortium Repository. To determine the combinatorial
effects of high fat diet with oncogenic K-Ras LSL-K-RasG12D/Ela-CreERT (LSL/BAC)
were constructed using the LSL-K-RasG12D mice expressing conditional knock-in
mutant K-RasG12Dand mice with a full length elastase gene promoter (Ela-CreERT)
was used to drive the expression of tamoxifen-regulated CreERT specific to adult
pancreatic acinar cells as previously described. LSL-K-RasG12D and Ela-CreERT
mice were bred to generate LSL-K-Ras/Ela-CreERT (LSL/BAC) double transgenic
mice resulting in targeted expression of K-rasG12D in adult mice pancreatic acinar
cells.

Furthermore, to determine the role of Cox-2 in K-Ras induced PanIN

formation, COXKO/LSL-K-RasG12D/Ela-CreERT (COXKO/LSL/BAC) were made by
crossing Cox-2 conditional knockout mice (Cox-2 KO) and LSL/BAC mice to
generate a triple transgenic mice with additional targeted deletion of Cox-2 and
expression of K-RasG12D in the pancreas acinar cell after Cre activation with
tamoxifen.
Additionally to further determine the survival rate and PanIN progression;
LSL/Pdx-1 (LSL/IPF) mice were also generated by crossing LSL-K-RasG12D with
pancreatic specific Cre (Pdx-1-Cre) mice that have targeted expression of KRasG12D in all embryonic cells of the pancreas during development. These animals
do not require the activation of Cre with tamoxifen for activation of oncogenic KRas.
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2.2 Treatment of animals.
2.2a Short term diet treatment of animals.
The treatment of all animals was reviewed and approved by the University of
Texas M.D. Anderson Institutional Animal Care and Use Committee.

LSL/BAC

animals, COXKO/LSL/BAC, and littermate control animals (BAC and COXKO/BAC)
were induced with tamoxifen through oral gavage for three consecutive days to
initiate oncogenic K-Ras expression starting at age 40 days. Animals were then
placed on either a high fat diet (HFD; Test Diet 58Y1- Van Heek DIO, Lab Supply,
Fort Worth) which contains 60% energy derived from fat (LSL/BAC; n=10 and BAC;
n=9), (LSL/Pdx-1; n=6 and Pdx-1; n=6) and (COXKO/LSL/BAC; n=9; COXKO/BAC;
n=5) or control diet (CD; Test Diet DIO 58Y2 Rodent Purified Diet, Lab Supply, Fort
Worth) which provides 10% energy from fat (LSL/BAC; n=8 and BAC; n=5),
(LSL/Pdx-1; n=5 and Pdx-1; n=5) and (COXKO/LSL/BAC; n=5 and COXKO/BAC;
n=5) on day three of tamoxifen induction. All animals were fed on diet for 30 days.
The body weight of each animal was measured weekly and after treatment, the
groups were sacrificed and pancreata were harvested for histology and protein
analysis.
2.2b Long term survival diet treatment of animals.
LSL/Pdx-1 and Pdx-1 animals were placed on their respective diets either
HFD or CD right after they were weaned and left on diet till they needed to be
sacrificed (70-100 days). LSL/BAC and BAC groups of animals were induced with
tamoxifen at 40 days and placed on either diet accordingly on the third day of
induction. They were left on diet till they had to be euthanized (150- days). The body
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weight of each animal was measured monthly and after treatment, the groups were
sacrificed and pancreata were harvested for histology and protein analysis. Survival
of animals was plotted using the survival curves on GraphPad Prism. The percent
change in body weight from day 1 to day 30 was calculated and graphed along with
the percent total pancreas weight/total body weight.
2.3 Ras activity assay.
Levels of GTP bound Ras was measured using a Raf pull-down assay kit
(Millipore, Bellerica). Snap-frozen pancreas samples were homogenized and
sonicated briefly on ice in lysis buffer containing 25 mM 4-(2-hydroxyl-ethyl)-1piperazineethanesulfonic acid (pH 7.5), 1% IGEPAL CA-630, 150mM NaCl, 0.25%
sodium

deoxycholate,

10%

glycerol,

25mM

NaF,

10mM

MgCl2,

1mM

ethylendediaminetetraacetic acid, 10 μg/ml aprotinin, 10 μg/ml leupeptin, and 1mM
sodium orthovanadate. The samples were centrifuged at 15,000 g for 20 minutes at
4°C to remove cellular debris and the lysates were collected. Equal concentrations
of total 700 g were incubated for 45 minutes at 4°C with agarose beads coated
with the Raf-Ras binding domain. 500ul of Mg2+ lysis buffer was used to wash the
beads three times, 30l of 4x loading buffer was added, lysates were vortexed,
centrifuged at 15,000g for 30 seconds at 4°C, then heated for 5 minutes at 95°C.
Protein levels of active and total Ras were measured by immunoblotting through a
western blot protocol. Quantification of bands was performed using an Odyssey
V3.0 instrument (LI-COR, Nebraska) and the densities of each sample for active
Ras/total Ras were plotted using Graphpad Prism 5.
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2.4 Western blot analysis.
Pancreas mouse tissue samples from each group were homogenized using
RIPA buffer. Lysates were prepared and either a 15% or 12% SDS-PAGE gel was
used to separate the proteins. Proteins were transferred from a SDS-PAGE gel to a
nitrocellulose membrane and blocked for 30 minutes at room temperature with 5%
non-fat dry milk in phosphate-buffered saline (PBS) containing 0.05% Tween 20.
Membranes were incubated at 4°C overnight with primary antibodies: Rabbit AntiGAPDH G9545 (1:1000; Sigma Aldrich), Mouse Anti-Ras 05-516 Clone 10 (1:1000;
Millipore), p-p44/42 MAPK (T202/Y204) p-ERK 9106S (1:1000; Cell Signaling), and
p44/42 MAPK (total ERK) 9102 (1:1000; Cell Signaling). Immunodetection of
proteins was performed using Alexa-Fluor goat anti-mouse 800 or goat anti-rabbit
680 conjugated secondary antibodies for detection with Odyssey Infrared Imaging
System (LI-COR Biosciences, Lincoln).

Images were converted to grayscale,

analyzed using Odyssey V3.0 and graphed.
2.5 Histology.
Pancreas tissue from mice were removed, washed with PBS, and incubated
in formalin overnight. The following day, formalin-fixed samples were embedded in
paraffin and sectioned onto slides at 5μm thick. Slides were then stained with
hematoxylin and eosin (H&E) and histological assessment was performed by a
pathologist. Slides were scored from 1-3 on the level of inflammation (1: scattered
immune cells, non-aggregating; 2: intermediate level of immune cells present; 3:
aggregates of immune cells within the pancreatic parenchyma forming a follicle-like
formation), fibrosis (1: occasional periductular or scant perilobular fibrosis; 2:
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intermediate level; 3: definite extensive fibrosis with resultant parenchymal (acinar)
atrophy, and frequency of PanIN lesions in each single lobule containing PanIN
lesions, irrespective of the number of cross sections of ducts present, was counted.
Each lesion was also scored on the grade of PanIN (PanIN-1, PanIN-2, or PanIN-3).
2.6 Immunohistochemistry.
Unstained paraffin embedded mouse pancreata were stained for: Rabbit antialpha smooth muscle actin ab5694 (1:1000; Abcam), and Rabbit p-ERK 4370
(1:100; Cell Signaling). Slides were deparaffinized using the standard procedure of
two washes of xylene, 100% Ethanol, 95% Ethanol, and one wash of 80% Ethanol.
Antigen retrieval was performed using DAKO target retrieval solution (10x
concentrate) with a steamer for 20 minutes at 98°C. The slides were allowed to cool
for 15 minutes and followed with endogenous blocking with H 2O2 for another 15
minutes. After washes with PBS slides were blocked with 1:12 fish gelatin for 1 hour
and incubated with primary antibody overnight at 4°C. Washes were done with PBS
and PBS containing 0.05% Tween 20. Sections were incubated with rabbit on
rodent horseradish peroxidase-labeled polymer RMR622H (Biocare) and positive
labeling was detected with DakoCytomation Liquid DAB+ Substrate System. Gill
no.3

hematoxylin

Immunohistochemical

solution
staining

was
for

used

to

counterstain

macrophages,

each

Anti-F4/80

Rat

section.
(1:20;

eBioscience), was performed after deparaffinization and antigen retrieval as
mentioned previously. Nonspecific binding was removed by endogenous blocking
with H2O2 and protein blocking with fish gelatin 1:12 from a 40% stock. After
washing, biotin goat anti-rat secondary was applied to sections followed by
incubation with streptavidin.
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2.7 Immunofluorescence.
Unstained OCT embedded frozen pancreas sections were fixed with cold
acetone for 10 minutes and then washed with PBS. Slides were then treated with
protein blocking solution (8% fish gelatin) for 20 minutes at room temperature.
Primary antibodies Cox-2 (1:300; Cayman Chemicals), iNOS (1: 100; Thermo
Scientific), F4/80 (1:50; eBioscience) was diluted in protein blocking solution and
applied overnight at 4°C. The next day, slides were washed in PBS, incubated in
protein blocking solution for 10 minutes and secondary antibody Alexa 594 Goat
Anti-rabbit (1:800; Life Technologies) diluted in protein blocking solution were
applied for 1 hour at room temperature. The samples were then washed and
counterstained with nuclear stain Hoechst 33342 (1:10000) for 10 minutes. After
nuclear staining the slides were washed, and coverslips were placed using
glycerol/PBS containing propyl gallate as mounting media. Slides were then
visualized under an epifluorescence microscope (Zeiss) and the total area and
intensity of fluorescence were measured using Simple PCI. The sum of the total
Cox-2 area for each tissue sample was divided by the sum of the total nuclear area.
Each sample was normalized to the average of all the LSL/BAC animals on CD.
2.8 Collagen Detection.
Collagen I fibers were observed by using paraffin embedded pancreatic
tissue and staining with Mason-Trichome stain (Sigma Aldrich). Deparaffinization
was performed as described above in the immunohistochemistry section. The tissue
samples were incubated in preheated Bouin’s solution, washed with water, and
stained with Weigert’s Iron Hematoxylin solution. This was followed by staining in
Biebrich

Scarlet-Acid

Fuchsin,

Phosphophotungstic/Phosphomolybdic
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Acid

Solution, and Aniline Blue Solution. The slides were then washed with 1% acetic
acid, washed, and rehydrated.
2.9 Statistics.
Data was analyzed using GraphPad software (Graphpad Prism Version 4.0
for Windows; GraphPad Software, San Diego, CA, www.graphpad.com). Results
are expressed as mean ± SEM. Data was analyzed by t-test or One-way ANOVA
and results are considered significant at p<0.05.

28

CHAPTER 3: RESULTS
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3.1 Introduction
Obesity is known as a major risk factor for pancreatic cancer, the fourth
deadliest malignancy in the United States (78). Several studies have stated a
correlation between elevated BMI and excess body weight with an increased risk of
developing pancreatic cancer (3, 12, 44, 45, 61, 68). There is also an established
link between childhood obesity and significant risk for PDAC. In the past two
decades, the rate of obesity has doubled to 59 million Americans because of the
adoption of a diet high in fat content. The increasing concern as obesity rates rise,
makes it even more important to determine the mechanistic molecular effects of a
high fat diet on PDAC development.
More than 90% of pancreatic cancer cases display an oncogenic mutation in
K-Ras (26, 35, 39, 43, 70). Ras is a guanine nucleotide binding protein (G-protein)
that is highly necessary for the function of cellular signaling pathways. In the normal
state, Ras is bound to GDP and remains in an inactive state until guanine exchange
factors (GEFs) that are controlled by growth factor receptors, cytokines, and other
signaling molecules remove the GDP and load GTP to Ras. This action exchanges
Ras from an inactive state to an active state to stimulate activation of
phosphoinositide 3-kinase (PI3-K), mitogen-activated protein kinase (MAPK), Ral,
and Cox-2 which are all necessary for cell growth, differentiation, and survival (39,
43, 70). Due to intrinsic GTP hydrolysis and interaction with GTPase activating
proteins (GAPs), hydrolysis of GTP to GDP returns Ras back to its inactive state
making the normal activity of Ras very transient. When an oncogenic mutation of KRas is present at codon 12, it prevents the ability of GAPs to help in the hydrolysis
of GTP to GDP, therefore prolonging the activity of Ras and making Ras
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constitutively active (39, 43, 52, 70). However, oncogenic K-Ras requires an
inflammatory stimulus to become activated. Once it is stimulated, it is slow to return
to basal levels and can go on to generate inflammatory mediators through activation
of NF-kB, Cox-2, and others. High Ras activity beyond the threshold can initiate the
inflammatory feed-forward loop in which these mediators can activate and prolong
K-Ras activity (14, 33).
An oncogenic mutation in K-Ras is present in the early stages of pancreatic
cancer at the formation of precancerous lesions known as pancreatic intraepithelial
neoplasia (PanINs), non-invasive ductal precursor lesions to invasive cancer (51).
Eventually, oncogenic K-Ras can lead to the accumulation of mutations in tumor
suppressors’ p53 and p16 which can advance the PanINs to higher grade PanINs
progressing towards PDAC. Inflammation and desmoplasia accompanies PanIN
formation in the initiation of this process (51). Therefore, we hypothesized that high
dietary fat could act as an inflammatory stimulus activating and prolonging
oncogenic K-Ras activity to initiate PDAC development. In addition, we predicted
high fat diet consumption starting at an early age would increase the progression of
PanIN development. To prove this we analyzed how diets with varying fat content
affected the pancreas of animals harboring an oncogenic K-Ras mutation and
examined it for an increase in inflammation, fibrosis, and PanIN formation. Along
with K-Ras, we investigated the important mediators that were crucial for this
reaction to occur by testing the expression of Cox-2 in pancreas acinar cells
expressing oncogenic K-Ras to determine if it was essential for high fat diet induced
inflammation, fibrosis, and PanIN development.
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We found that high fat diet consumption in the presence of oncogenic K-Ras,
accelerated and progressed PanIN development, fibrosis, and inflammation using a
mouse model that recapitulates the potential human dietary fat risk. These animals
had elevated Ras-GTP levels and increased downstream signaling. We also saw
survival rates were decreased in animals on high fat diet. In addition, we were also
able to show a direct link between Cox-2 and K-Ras indicating it is a key regulator
of these events. Therefore, these results show K-Ras to be a key protein involved in
cancer initiation and shows Cox-2 to be critical for these events, suggesting
potential intervention possibilities for prevention.

3.2 Combinatorial Effects of High Fat Diet and Oncogenic K-Ras
3.2.1 High fat diet increases the total body weight and pancreas weight
Animals were induced with tamoxifen for three days to activate expression of
oncogenic K-Ras and placed on either a control or high fat diet for thirty days
(Figure 3.1). Cre-mediated conditional oncogenic K-Ras knock-in mice (LSL/BAC)
expressing endogenous levels of oncogenic K-Ras specifically in the pancreatic
acinar cells were compared to the littermate controls (BAC).The group of animals
treated with diet containing 60% energy from fat for thirty days, gained weight
rapidly compared to animals on the control diet containing 10% energy from fat
(Figure 3.1). After thirty days of dietary treatment, BAC and LSL/BAC on high fat
diet doubled their body weight and had excess fatty deposits throughout the
peritoneal cavity in comparison to mice fed a control diet (Figure 3.1). Additionally,
only animals expressing oncogenic K-Ras fed a high fat diet had increased
pancreas weight compared to other groups.
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Figure 3.1 High fat diet increased total body in all mice and pancreas weight in
mice expressing oncogenic K-Ras. BAC and LSL/BAC mice were induced with
tamoxifen for three days and on day three was placed on respective diets for 30 days
(A). All groups were weighed once every week and the percent change from week 1 to
week 5 of treatment was calculated. BAC and LSL/BAC mice fed a HFD (60% kcal of
fat) had a greater change in weight (**p= 0.0047 LSL/BAC HFD vs. LSL/BAC CD and
#p=0.0295 LSL/BAC HFD vs. BAC mice on CD; ***p= 0.0003 BAC HFD vs. LSL/BAC
mice on CD, and ##p=0.0031 BAC HFD vs. BAC CD) compared to the mice fed a CD
(10% kcal of fat) (B). On day 30 the mice were sacrificed and the pancreas was
removed, weighed and the percent weight of the pancreas/the total body weight was
graphed for all groups. Mice expressing oncogenic K-Ras and fed the HFD had a
significantly greater pancreas weight compared to BAC animals on HFD and CD, as
well as LSL/BAC animals on CD (**p=0.0030 LSL/BAC HFD vs. LSL/BAC CD;
**p=0.0031 LSL/BAC HFD vs. BAC CD; **p=0.0012 LSL/BAC HFD vs. BAC HFD) (C).
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3.2.2 High fat diet initiates inflammation, fibrosis, and the formation of PanIN lesions
BAC control mice and LSL/BAC mice fed either a control or high fat diet were
histologically accessed for morphologically changes within the pancreas (Figure
3.2). BAC animals had normal pancreata and were indistinguishable from each
other after thirty days of treatment with respective diets. LSL/BAC mice expressing
endogenous levels of oncogenic K-Ras fed a control diet infrequently developed
small areas of fibrosis or PanINs. In contrast, LSL/BAC mice on high fat diet
developed extensive areas of fibrosis accompanied by multiple PanIN-1 lesions.
Each pancreas sample was also scored on the level of inflammation, fibrosis, and
the number of PanIN lesions present throughout the specimen (Figure 3.2). When
LSL/BAC animals fed a control diet were compared to those on high fat diet, the
level of inflammation and fibrosis was significantly higher. Similarly, those on high
fat diet had six-fold the number of lobules containing PanIN-1 lesions. The
consumption of high fat diet in the presence of oncogenic K-Ras mutation in the
pancreas could initiate and accelerate the formation of PanIN lesions, which is an
established early step in the initiation of pancreatic cancer.

3.2.3 High fat diet increases infiltration of inflammatory mediators into the pancreas
Animals treated with both control and high fat diet was analyzed for signs of
inflammation specifically for the presence of immune cells such as macrophages
(Figure 3.3). Macrophages are the first responders of the body’s innate response
when a pathogen invades the body and releases pro-inflammatory cytokines that
can recruit lymphocytes and other immune cells to help fight the infection.
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Figure 3.2 Consumption of a high fat diet led to large areas of fibrosis,
inflammation, and PanIN lesions throughout the pancreas. Representative H&E
stain of BAC animals on CD (A), and HFD (B), oncogenic K-Ras LSL/BAC animals on
CD (C) and HFD (D) showed high fibrosis and areas of precancerous lesions in HFD
fed oncogenic K-Ras expressing mice. Littermate controls had a healthy pancreas after
30 days of treatment regardless of diet. Each tissue sample was scored on the level of
inflammation, fibrosis, and precancerous lesions (average of number of PanIN-1
lesions) seen in the entire tissue. LSL/BAC mice on HFD had a significantly higher level
of inflammation (**p=0.009 LSL/BAC HFD vs. LSL/BAC CD; ###p=0.0008 LSL/BAC
HFD vs. BAC CD; ###p=0.0009 LSL/BAC HFD vs. BAC HFD; and *p=0.0433 LSL/BAC
CD vs. BAC CD) (E) and fibrosis than mice on CD (*p=0.0108 LSL/BAC HFD vs.
LSL/BAC CD; ###p<0.001 LSL/BAC HFD vs. BAC CD; ###p=0.0006 LSL/BAC HFD vs.
BAC HFD) (F). Each sample was graded based on the number of PanIN lesions in the
entire tissue. Only PanIN-1 lesions were found in all the tissues. HFD fed LSL/BAC
mice had significantly higher number of precancerous lesions (*p=0.0162 LSL/BAC
HFD vs. LSL/BAC CD; ###p<0.001 LSL/BAC HFD vs. BAC HFD and CD) (G).
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We predicted that animals consuming a high fat diet when an oncogenic mutation of
K-Ras was present within the acinar cells of the pancreas would have a greater
recruitment

of

macrophages,

as

well

as

other

inflammatory

mediators.

Immunohistochemical staining of F4/80+, a marker for most mature macrophages,
of BAC animals on control and high fat diet showed no signs of macrophages in the
tissue. Additionally, LSL/BAC animals on control diet had low levels of inflammation.
In contrast, LSL/BAC animals on high fat diet had an increased infiltration of F4/80+
macrophages around the areas of PanIN lesions (Figure 3.3).

Figure 3.3 Consumption of High Fat Recruits Macrophages into the
Pancreas. Staining for F4/80+ macrophages on BAC animals on CD (A), HFD
(B) LSL/BAC animals on CD (C), and HFD (D). LSL/BAC animals on HFD
demonstrate strong macrophage infiltration.
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Another inflammatory marker that is used is inducible nitric oxide synthase
(iNOS), which is commonly released by macrophages, endothelial cells, and
stromal cells. In the presence of inflammation, these cells rapidly express iNOS
producing large amounts of nitric oxide, a free radical gas important for infectious
and anti-tumor mechanism of the innate immunity.

Figure 3.4 Inflammatory iNOS production is increased by a high fat diet.
Immunofluorescence tissue staining for iNOS of BAC animals on CD (A), HFD (B)
LSL/BAC animals on CD (C), and HFD (D) indicated higher iNOS expression in
mutant K-Ras animals on HFD than on mice on CD. Quantification of intensity and
area of fluorescence of iNOS in the pancreas showed a significant increase in
iNOS expression in LSL/BAC animals on HFD (**p=0.0083 LSL/BAC high fat vs.
LSL/BAC CD) (E).
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Overproduction of nitric oxide is present in many cancers leading to oxidative stress
and tissue damage. BAC animals on control and high fat diet had low levels of iNOS
as predicted because the pancreases were completely normal (Figure 3.4).
LSL/BAC animals on high fat diet had increased levels of iNOS production in the
fibrotic areas of the tissue compared to LSL/BAC animals on control diet (Figure
3.4).
Similarly, levels of Cox-2, an enzyme activated by Ras and involved in
formation of biological mediators involved in inflammation like prostaglandin E2
(PGE2), was analyzed by immunofluorescence (Figure 3.5). Levels of Cox-2 were
significantly elevated in LSL/BAC animals fed a high fat diet. LSL/BAC animals on
control diet and the littermate control animals on either diet had low levels of Cox-2
expression in the pancreas. Immunohistochemistry staining for co-localization of
Cox-2 and F4/80+ macrophages indicates that Cox-2 is highly present in the PanIN
lesions and is also expressed by macrophages within the tissue.

3.2.4 High fat diet induces excessive fibrotic stroma formation
PDAC consists predominately of fibrotic stoma and only 10-20% of the tumor
mass is made up of cancer cells. Fibrosis is a major early initiating step in
pancreatic cancer and is activated by a pancreas specific myofibroblast cell called
pancreatic stellate cells (PSCs). Normally, in the presence of inflammation in the
pancreas, quiescent PSCs in the stroma will become activated and migrate to areas
of injury. PSCs will then produce extracellular matrix proteins such as collagen I and
alpha smooth muscle actin (αSMA), known as markers for these cells. We

38

hypothesized that when animals expressing oncogenic K-Ras are fed a high fat diet,
quiescent PSCs will become activated and produce excess stromal formation.

Figure 3.5 High fat diet acts an inflammatory stimulus in the pancreas,
increasing the level of Cox-2. Immunofluorescence tissue staining for Cox-2
on BAC animals on CD (A), HFD (B) LSL/BAC animals on CD (C), and HFD (D)
indicated higher Cox-2 expression in mutant K-Ras animals on HFD than on
mice on CD. Quantification of intensity and area of fluorescence of Cox-2 in the
pancreas showed a significant increase in Cox-2 expression in LSL/BAC
animals on HFD (***p<0.0001 LSL/BAC high fat vs. LSL/BAC CD) (E).
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Trichome Mason Staining of pancreata from BAC mice on either diet and LSL/BAC
mice on control diet showed normal collagen production around the blood vessels
(Figure 3.6). However, LSL/BAC mice on high fat diet had increased levels of
stromal collagen I throughout the pancreas. Likewise, immunohistochemical
staining to detect presence of αSMA, an indicator of activated stellate cells,
indicated elevated expression levels in LSL/BAC mice on high fat diet compared to
LSL/BAC mice on control diet and littermate controls on either diet (Figure 3.6).
Both stains support the potential of high fat diet in activating stellate cells,
increasing stromal activity resulting in definite fibrosis.

3.2.5 High fat diet can stimulate oncogenic K-Ras activation and its downstream
targets
To determine if a high fat diet could increase Ras activity in mice expressing
endogenous levels of oncogenic K-Ras, we measured levels of GTP-bound Ras in
the pancreas of all mice through a Raf-pull down assay (Figure 3.7). LSL/BAC
animals on high fat diet had significantly amplified activated Ras levels compared to
LSL/BAC

animals

immunohistochemistry

fed

with

analysis

control
indicated

diet.
that

Further,
levels

western
of

blot

and

phospho-ERK,

a

downstream target of activated K-Ras, were elevated in LSL/BAC animals on high
fat diet (Figure 3.7). This supports the potential of high fat diet to stimulate
oncogenic K-Ras activation and increase its downstream activity. Phospho-ERK
elevation was not seen in LSL/BAC mice fed a control diet.
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Figure 3.6 High fat diet increases stromal activity in mice with mutant KRas. Collagen staining of BAC animals on CD (A), HFD (B) LSL/BAC animals
on CD (C), and HFD (D) showed high levels of collagen production in LSL/BAC
animals fed a HFD. Immunohistochemical staining for alpha-smooth muscle
actin was also performed as another marker for stromal activity for BAC animals
on CD (E), HFD (F) LSL/BAC animals on CD (G), and HFD (H). It further
supported high stromal activity in HFD fed LSL/BAC mice by increased
expression of alpha-SMA.
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Figure 3.7 Activation of Ras downstream pathways were increased significantly
by HFD. Ras activity was also measured through Raf-pull down assay and correlated
with Phospho-ERK expression levels. LSL/BAC animals on HFD had a significantly
higher Ras activity compared to BAC and LSL/BAC animals on CD (**p=0.0087
LSL/BAC HFD vs. LSL/BAC CD; **p=0.0095 LSL/BAC HFD vs. BAC CD; #p=0.0381
LSL/BAC HFD vs. BAC HFD) (A). Western blot analysis for phospho-ERK supported
this observation by demonstrating a significantly higher Phospho-ERK expression in
HFD fed LSL/BAC mice compared to BAC mice and LSL/BAC mice on CD
(**p=0.0043 LSL/BAC HFD vs. LSL/BAC CD; **p=0.0095 LSL/BAC HFD vs. BAC CD;
#p=0.0476 LSL/BAC HFD vs. BAC HFD) (B). Immunohistochemical staining of
phospho-ERK for BAC animals on CD (C), HFD (D) LSL/BAC animals on CD (E), and
HFD (F) showed substantial Phospho-ERK activity concentrated in mice expressing
oncogenic K-Ras on HFD.
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3.2.6 Cox-2 is essential for high fat diet induced fibrosis in mice with oncogenic KRas
Normally, activation of K-Ras leads to downstream activation of Cox-2 and
PGE2 needed for inflammation in our bodies. We predicted that Cox-2 would be
elevated in animals expressing oncogenic K-Ras fed a high fat diet. To determine
the mechanistic effects of high fat diet specifically in the pancreas, we examined
pancreatic Cox-2 levels and were able to identify that high levels of Cox-2 was
present in LSL/BAC animals treated with high fat diet (Figure 3.5). To further
analyze the role of Cox-2, LSL/BAC mice were crossed with Cox-2 conditional
knockout mice to produce triple transgenic mice that have oncogenic K-Ras
expression but lack Cox-2 expression in the acinar cells. COXKO/LSL/BAC and the
littermate control animals (COXKO/BAC) were treated with either control diet or high
fat diet for thirty days. No signs of inflammation, fibrosis, or PanIN lesions were
evident in any of the groups regardless of treatment with high fat diet (Figure 3.8).
Further, samples were assessed for the level of inflammation, fibrosis, and number
of PanIN foci present within the tissue and COXKO/LSL/BAC animals on high fat
diet were compared to BAC and LSL/BAC animals on control or high fat diet (Figure
3.8). The levels of inflammation, fibrosis, and PanIN lesions were markedly
decreased in COXKO/LSL/BAC animals on high fat diet (Figure 3.8). Additionally,
Ras activity was significantly decreased in animals with the expression of oncogenic
K-Ras but lacking Cox-2 in the acinar cells (Figure 3.9). This was true for
COXKO/LSL/BAC animals regardless of the diet. This data supports the hypothesis
and indicates a critical importance of Cox-2 in initiating inflammation and acinar cell
metaplasia into PanIN lesions caused by high fat diet consumption. Furthermore it
43

specifies the necessity for Cox-2 to increase Ras activity above the threshold to
induce these reactions.

Figure 3.8 Cox-2 deletion in the pancreas blocks K-Ras induced effects of
high fat diet. Histology of conditional Cox-2 knockout mice without oncogenic
K-Ras expression treated with CD (A), HFD (B), and Cox-2 knockout mice with
oncogenic K-Ras expression fed CD (C) and HFD (D) displayed a healthy,
normal pancreas with no signs of inflammation, fibrosis, or PanIN lesions.
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Figure 3.9 Cox-2 deletion prevents the activation of oncogenic K-Ras.
Quantification of fibrosis, inflammation and PanINs, for COXKO/LSL/BAC animals
treated with CD and HFD compared to BAC and LSL/BAC animals data shown in
Figure 3.2. Tissue samples were scored and LSL/BAC animals on HFD had
substantially higher levels of inflammation (***p=0.0002 LSL/BAC HFD vs.
COXKO/LSL/BAC HFD) (E) , fibrosis (***p=0.0001 LSL/BAC HFD vs.
COXKO/LSL/BAC HFD) (F) , and number of PanIN-1 lesions (***p=0.0005
LSL/BAC HFD vs. COXKO/LSL/BAC HFD) compared to COXKO/LSL/BAC
animals (G). Ras activity was also compared between LSL/BAC and
COXKO/LSL/BAC animals on CD and HFD (H). There was a significant reduction
in Ras activity in COXKO/LSL/BAC animals on either diet compared to LSL/BAC
animals (*p=0.026 LSL/BAC HF vs. COXKO/LSL/BAC CD; **p=0.005 LSL/BAC HF
vs. LSL/BAC CD and COXKO/LSL/BAC HF).
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3.3 Influence of High Fat Diet on Tumor Progression and Survival Rate
3.3.1 High fat diet decreases survival rate in animals expressing oncogenic K-Ras
To determine how long the animals would survive if left on the respective
diets longer than thirty days, BAC and LSL/BAC animals were fed with control or
high fat diet starting at thirty days of age and left till they needed to be sacrificed.
LSL/BAC animals on high fat diet had significant decrease in survival rate and
survived up to only 250 days compared to those animals on control diet which
survived much longer (Figure 3.10).

Figure 3.10 High fat diet decreased overall survival rate in animals with
oncogenic K-Ras. LSL/BAC animals on CD and HFD were started on diet after
induction with tamoxifen and monitored daily for survival. Animals on HFD had a
significant reduction in survival rate compared to control animals which remain alive
(*p=0.0214) (A). Similarly, LSL/Pdx-1 mice were monitored for survival after
treatment with either diet and animals on high fat diet had a decrease in overall
survival (*p=0.0233) (B).
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Additionally, LSL/Pdx-1 mice, expressing oncogenic K-Ras in all the cells of the
pancreas at development, were also placed on control or high fat diet to determine if
high fat diet could decrease survival. Similar to LSL/BAC animals, LSL/Pdx mice on
high fat diet survived up to 145 days on the diet while animals on control diet
survived about 220 days (Figure 3.10). This data supports the ability of high fat diet
to decrease survival in animals expressing an oncogenic mutation in K-Ras.

3.3.2 High fat diet accelerates progression of PanIN-2 and PanIN-3 formation
Corresponding with overall survival, animals on high fat diet had an
acceleration of PanIN formation which progressed at a rapid rate. LSL/Pdx-1 and
LSL/BAC animals fed either a control or high fat diet had drastic histological
differences in their pancreata (Figure 3.10). LSL/Pdx-1 animals sacrificed after 90
days of high fat diet consumption had extensive fibrosis and inflammation
accompanied by foci containing PanIN-2 and PanIN-3. This varied significantly from
LSL/Pdx-1 animals sacrificed forty days later which only contained PanIN-1 foci
throughout the pancreata. Scoring of level of inflammation, fibrosis, and PanIN level
showed significantly elevated levels compared to LSL/Pdx-1 animals on control diet
(Figure 3.11). LSL/Pdx-1 animals on high fat diet had increased number of PanIN
foci with progression to PanIN-2 and PanIN-3 (Figure 3.11). Similarly, LSL/BAC
animals fed either diet had a linear trend and animals sacrificed at 160 days
displayed prominent accelerated PanIN formation and cystic lesions in animals on
high fat diet (Figure 3.12). This phenomenon was not present in LSL/BAC animals
on control diet which exhibited small areas of low grade PanIN formation. Further
treatment of the respective diets induced a severe desmoplastic reaction with
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progression to invasive pancreatic cancer after 205 days of high fat diet (Figure
3.12).

Figure 3.11 HFD accelerates cancer development in Pdx-Cre-K-Ras
G12D. Histological assessment of the pancreas of Pdx-Cre mice days on CD (A),
HFD (B), Pdx-Cre-K-RasG12D mice on CD (C) and HFD (D) treated 70-100
shows a drastic progression of PanIN lesion formation in Pdx-Cre-K-RasG12D
animals on HFD. Each sample was scored on the level of inflammation, fibrosis,
and the number of each grade of PanINs present in the entire tissue. Pdx-Cre-KRasG12D mice on HFD had significantly higher levels of inflammation
(**p=0.0056), fibrosis (**p=0.0056), and number of PanIN-1 lesions (*p=0.00115)
than Pdx-Cre-K-RasG12D on CD. Pdx-Cre-K-RasG12D mice on HFD had large
areas of reactive stroma accompanied with the presence of PanIN-2 and PanIN-3
lesions that were not seen in animals on CD.
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The tumor burden in LSL/BAC animals on high fat diet was significant. These
LSL/BAC animals developed metastasis to the lungs and liver unlike the control diet
fed animals which did not demonstrate this phenotype.

Figure 3.12 High fat diet accelerated PDAC and metastasis in LSL/BAC
animals. Pancreata of LSL/BAC animals on CD or HFD was compared and
LSL/BAC animals on HFD obtained a large tumor in the pancreas while the
LSL/BAC animals on CD signs of fibrosis (A) Pancreata of HFD had large cysts
compared to animals on CD and lung metastasis was present (B). Histological
assessment of the pancreas of mice fed CD sacrificed at 160 days (C) compared
to an animal sacrificed at 205 days (D) shows an increase in fibrosis. In contrast,
shows extensive cystic regions and accelerated PanIN formation in animals was
observed in LSL/BAC animals on HFD at 160 days (E). Comparison to LSL/BAC
animals at 205 days indicates a rapid progression to PDAC (F).
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CHAPTER 4: DISCUSSION
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4.1 Introduction
Recent evidence has shown a strong link between high fat diet induced
obesity and pancreatic cancer but very little is known about the mechanism
involved. Since K-Ras is highly mutated in pancreatic cancer, our study specifically
investigated if oncogenic K-Ras increases the risk of developing pancreatic cancer
when a high fat diet is consumed. Our data supports the ability of a high fat diet in
the presence of physiologically relevant levels of oncogenic K-Ras in adult
pancreatic acinar cells to initiate pancreatic cancer development (Figure 4.1).
Further, it demonstrated the rapid progression of PanIN lesions and decreased
overall survival when the high fat diet consumption was prolonged. To address this
question, we used for the first time, an acinar specific K-Ras model. Previous work
has indicated a high fat diet can accelerate PanIN development in p48Cre -K-RasLSLG12D/+

, a less specific acinar-Cre mouse model (42). It was also evidenced that

tumor promotion is associated with inflammation and TNFR1 signaling showing a
role of TNF-α in enhancing PanIN formation (42). Additionally, this study
demonstrated that high fat diet does cause changes in metabolic function seen by
insufficiency in the exocrine gland (42). This model, unlike the acinar-Ras mice,
develops spontaneous PanINs early in development because it utilizes an
embryonic promoter to drive the expression of oncogenic K-Ras in all the cells of
the pancreas. Therefore, although it demonstrates that high fat diet does increase
PanIN formation and result in metabolic dysfunction in the pancreas, it is not an
accurate physiological representation of the true effects of high fat diet. Pancreatic
cancer is not disease of infancy and tumors arise in adult individuals. Therefore, in
contrast, our model more closely mimics human disease due to the lack of
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spontaneous pathologies in mice expressing endogenous levels of K-Ras only in
the adult acinar cells (14, 22, 33).

4.2 Mechanistic Link Between High Fat Diet and Pancreatic Cancer
The association between obesity and growth of pancreatic cancer was
observed in xenograft tumors. Orthotopic implantation of human pancreatic cancer
cells (Mia PaCa2) into mice fed a high fat diet drastically increased tumor burden
(84). Although there was strong evidence suggesting a connection between cancer
promotion and a high fat diet, a mechanistic conclusion was lacking. Additionally,
although it is important to note that cancer growth can be increased, the
mechanisms involved in growth of cancer are different than those seen in cancer
initiation, and the mechanisms of cancer initiation could provide ideas for prevention
of pancreatic cancer risk caused by a high fat diet.
Oncogenic point mutation in K-Ras is the earliest recorded mutation
occurring during the normal epithelial cell transformation to PanIN lesions (16, 17,
31, 35, 47, 56). Although mutations in K-Ras are mostly associated with cancer,
large subsets of healthy individuals who never develop PDAC also harbor K-Ras
mutations in their pancreas (35, 81). In fact, oncogenic K-Ras requires an
inflammatory stimulus for activation and stimulation beyond the pathological
threshold, increase K-Ras activity eventually leading to pancreatic cancer. This
concept was recently demonstrated when mice carrying an oncogenic K-Ras
mutation and treated with caerulein, LPS or elevated cholecystokinin (CCK) levels
to induce inflammation, resulted in a Cox-2 mediated feed-forward loop driving
sustained K-Ras activity (14). Our study indicated the ability of high fat diet to also
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act as an inflammatory agent to trigger the activation of oncogenic K-Ras and its
downstream targets, specifically phospho-ERK in LSL/BAC animals (Figure 4.1).
Ras activity and phospho-ERK was highly increased in these animals supporting
the ability of a high fat diet to sustain high K-Ras activity. This data is crucial in
understanding the possible mechanistic link between oncogenic K-Ras and obesityinduced acceleration of normal acinar cell transformation into ductal lesions.
High fat diet also increased the stimulation of quiescent pancreatic stellate
cells inducing increased stromal formation (Figure 4.1). The role of PSCs and the
stromal microenvironment in pancreatic cancer is currently not understood. Despite
this, active PSCs are universally present in the early stages of PDAC and predicted
to promote pancreatic cancer progression (60). Stellate cell activation is primarily
due to inflammatory mediators and not a response to acinar cell damage or death,
since acinar cell apoptosis does not activate PSCs (20). Our study demonstrated
the impact of high fat diet on promoting high levels of inflammation seen by
increased infiltration of macrophages, as well as the elevated levels of Cox-2 and
iNOS (Figure 4.1). Levels of iNOS are elevated in many cancers and thought to
promote cancer growth (85). The induction of iNOS by macrophages and epithelial
cells could aid in fibrosis and PanIN formation.
Moreover, acinar cells containing high Ras activity can release mediators
that can aid in this process, initiating fibrosis. Similarly, animals expressing
oncogenic K-Ras had increased

fibrosis by showing high levels of ATC2 and

collagen I that are normally produced by PSCs. Mediators released by mutated KRas influence acinar cells could have been involved in the recruitment of immune
cells, activating PSCs and instigating stromal formation. Recently, we established
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PGE2 as a mediator involved in stellate cell activation (13). Therefore, Cox-2
activity induced by oncogenic K-Ras is a possible mechanistic explanation for
development of fibrotic stroma.
Along with the increased levels of inflammation and fibrosis observed in this
study, we were also able to validate that high fat diet can stimulate oncogenic KRas activity to drive the initiation of PanIN lesion formation. All animals on high fat
diet had pronounced PanIN-1 formation compared to our animals on control diet in
only thirty days of treatment with either diet. This study proves the importance of an
oncogenic mutation in K-Ras in instigating the early development of PDAC.
Additionally, it emphasizes the elevated risk of developing PDAC in the presence of
oncogenic K-Ras and consumption of high dietary fat.
As mentioned previously, Cox-2 is highly important in the inflammatory
positive feed forward loop enhancing oncogenic K-Ras activity (14). To support this
finding, our data illustrates Cox-2 was essential for the high fat diet induced effects
on oncogenic K-Ras activity, as well as stromal and PanIN lesion development
(Figure 4.1). Interestingly, although our data shows K-Ras is the primary driving
mechanism in the promotion of PDAC development, it requires the presence of
Cox-2 to activate and mediate the Ras feed forward loop sustaining high oncogenic
K-Ras activity. A recent paper illustrating the ability of high fat diet to accelerate
PanIN formation, also demonstrated a link between TNF-α and tumor promotion in
high fat diet induced obesity (42). Since it is known that in obesity, levels of TNF-α
are significantly increased and that TNF-α is an activator of NF-κB, this finding
correlates with our data. This observation could be a key mechanistic explanation
for the protective effect of Cox-2 inhibitors, such as aspirin, on reducing pancreatic
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cancer risk and could present a possible method for prevention for obesity related
syndrome causing PDAC.

Figure 4.1: Mechanistic link between high fat diet and oncogenic K-Ras. HFD
causes inflammation in the pancreas which leads to oncogenic K-Ras
activation. Activation of oncogenic K-Ras leads to the downstream activation of Cox2, Phospho-ERK, and infiltration of macrophages into the stroma, as well as
activation of quiescent stellate cells producing extracellular matrix proteins; alpha
SMA and collagen I increasing stromal activity. Cox-2 stimulates a positive feed
forward loop increasing K-Ras activity and further enhancing inflammation, fibrosis,
and the recruitment of inflammatory mediators to the pancreas. Therefore, the
presence of Cox-2 is essential in the promotion of oncogenic K-Ras activity to initiate
PanIN formation.
55

4.3 Progression to PDAC with High Fat Diet
Since a mechanistic link was established between oncogenic K-Ras and high
fat diet, it was essential to determine how continuous consumption could enhance
this reaction. Previously, we observed PanIN-1 development accompanied by
extensive fibrosis and inflammation after only thirty days of treatment with high fat
diet. A recent study had shown that treatment of LSL/Pdx-1 mice, expressing
oncogenic K-Ras in all the cell of the pancreas, with a high fat diet progressed
PanIN-2 and PanIN-3 development (42). In this current study, we validated the
results from this model and also used an acinar specific oncogenic K-Ras model
(LSL/BAC). Both studies indicated the ability of high fat diet to accelerate PanIN
development. LSL/Pdx-1 mice advanced PanIN formation with widespread fibrosis
and inflammatory cell invasion as was noted in the previous studies. LSL/BAC
animals on high fat diet had a rapid progression of PanIN development and after six
months animals had developed pancreatic cancer. Furthermore, not only did the
animals have localized tumor in the pancreas, the cancer had metastasized to the
liver and lungs. These results were not seen in the animals fed the control diet.
In addition, we were able to record the overall survival of these animals
through the course of dietary treatment. It was previously recorded in several cohort
and epidemiology studies that obesity decreased overall survival in individuals with
pancreatic cancer (45). We confirmed this observation by showing continuous
treatment with high fat diet significantly decreased survival compared to the control
diet. In fact, LSL/Pdx-1 animals on high fat diet survived up to 150 days compared
to our control animals that survived about 250 days. Similarly, LSL/BAC animals on
high fat diet became sick at a rapid rate while majority of the control animals remain
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alive. Overall, these studies accurately demonstrated the elevated risk of
developing cancer early associated with high fat diet consumption by the rapid
progression of PanIN development leading to invasive cancer, as well as the
reduction in overall survival. This observation provides clear evidence suggestive
for prevention of pancreatic cancer by reduction of dietary fat.

4.4 Future Directions
Although this work has accurately associated an oncogenic K-Ras mutation
with initiating the development of PDAC when animals were treated with a high fat
diet, there still remains many unanswered questions. It is important to determine the
actual mechanism of how high fat diet activates oncogenic K-Ras and if
inflammation is a result of oncogenic K-Ras activation or a cause. Furthermore, it
would be essential to investigate further the role of Cox-2 in this reaction to
understand how deletion of Cox-2 eliminates the high fat diet induced fibrosis and
PanIN formation. Since COXKO/LSL/BAC animals were only treated with the
control and high fat diet for thirty days, we can conclude that deletion of Cox-2 in
acinar cells delay K-Ras mediated high fat diet induced PanIN formation. However,
it would be critical to determine the long term effects of this treatment on these
animals.
It would also be important to determine the other inflammatory mediators
involved and which are upregulated or downregulated in this process. Protein
analysis of tissues could also provide information on the other proteins affected by
high fat diet consumption and how K-Ras and Cox-2 might enhance or decrease
their activity. Obesity related markers such as leptin, TNF-α, adiponectin, and
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others should also be evaluated to determine how adipose tissue secreted
molecules could enhance K-Ras mediated PanIN development. This will give a
complete understanding of the relationship between obesity, systemic inflammation,
and how they may work together to potentially induce oncogenic K-Ras in the
pancreas leading to fibrosis and PanIN development.
Along with the added mechanistic knowledge that is necessary to understand
this pathology, knowing that continuous high fat diet consumption accelerates
PanIN progression to PDAC in only six months in mice expressing oncogenic KRas, demonstrates the necessity for prevention tactics. Potential Cox-2 inhibitors
could be studied to block inflammatory Cox-2 feed forward loop increasing Ras
activity resulting in early PanIN formation. Additionally, antioxidants have also been
previously shown to reduce cancer risk and could be tested in this mouse model as
a potential preventative treatment. With the rise in obesity, it is even more
necessary to fight this epidemic and decrease cancer risk.
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